Protocolos de Atención Integral, una estrategia para las enfermedades crónicas

Authors

Keywords:

Enfermedades no Transmisibles, Evaluación de Procesos, Atención de Salud, Administración de los Servicios de Salud / Noncommunicable Diseases, Process Assessment, Health Care, Health Services Administration

Abstract

Abstract

Noncommunicable diseases (NCD) cause more than 41 million deaths each year, equivalent to 71% of all deaths globally. The main types of NCD are: cardiovascular diseases (heart attack or cerebrovascular infarction), diabetes, cancer and chronic respiratory diseases (chronic obstructive pulmonary disease and asthma). In Mexico, NCD are responsible of more than three-quarters of deaths. This supplement describes a novel strategy by the Instituto Mexicano del Seguro Social (IMSS) to confront chronic diseases, known as Comprehensive Care Protocols, which aim to be a simple and easy-to-interpret reference document, but at the forefront of national and international knowledge, based on scientific evidence and normative documents. In addition, they specify the indispensable, optional actions and those that have to be avoided by the expanded health team. Therefore, this tool will guide our actions according to scientific advances and social needs.

Downloads

Download data is not yet available.

Author Biography

  • Célida Duque-Molina, Intituto Mexicano del Seguro Social, Dirección de Prestaciones Médicas. Ciudad de México, México

    Directora de Prestaciones Médicas.

References

 

GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388 (10053):1659-1724.

 

Organización Mundial de la Salud. Enfermedades no transmisibles. Ginebra, Suiza: OMS; 2021. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/ noncommunicable-diseases.

 

Laslett LJ, Alagona P, Clark BA, Drozda JP, Saldivar F, Wilson SR, et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol. 2012;60(25 Suppl):S1-49.

 

Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, et al. Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378 (9798):1231-43.

 

Instituto Nacional de Estadística y Geografía. Comunicación Social. Estadística De Defunciones Registradas 2020. Preliminar. Ciudad de México, México: INEGI; 2020.

 

Eberly LA, Rusangwa C, Ng’ang’a L, Neal CC, Mukundiyukuri JP, Mpanusingo E, et al. Cost of integrated chronic care for severe non-communicable diseases at district hospitals in rural Rwanda. BMJ Glob Health. 2019;4(3):e001449.

 

Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356(23): 2388-98.

 

Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U. EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16(2):121-37.

 

Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other preexisting comorbidities with COVID-19 mortality: A systematic review and meta-analysis. PLoS One. 2020;15(8):e0238215.

 

Borrayo G, Rosas M, Ramírez E, Saturno G, Estrada J, Parra R, et al. RENASCA IMSS group. STEMI and NSTEMI: Realworld Study  in Mexico (RENASCA). Arch Med Res. 2018;49 (8):609-19.

 

Downloads

Published

2022-02-08 — Updated on 2025-06-13

Versions

Issue

Section

Editorial